-The Hindu The Bali ministerial conference in December presents a crucial opportunity to bring about changes in WTO rules Ending hunger and poverty requires major national policy initiatives in developing countries. The United Nations Secretary-General has articulated a broad zero hunger vision, endorsed and embraced as a priority by national leaders in many developing countries in Latin America, Africa and Asia. Production of food by small cultivators in developing countries has a...

-The Hindu Unless a deeper, institutional change is ushered in to break the nexus between drug companies and the regulatory regime, Indians consuming drugs may be exposing themselves to serious risks Even before I walked into the Mayflower Hotel in the heart of Washington on a crisp autumn afternoon to meet Dinesh Thakur, whistle-blower and former director of India-based pharmaceutical giant Ranbaxy, I had a hunch that this conversation would spark some...

-Economic and Political Weekly The government has notified a Draft Land Reforms Policy which, on paper, has all the requisites of an earnest programme. Yet, the near total failure of earlier efforts at land reforms in India leave little room for hope that something substantial will at last be done to combat landlessness. Harsh Mander (manderharsh@gmail.com) is with the Centre for Equity Studies, New Delhi, and works with survivors of mass violence,...

-The Indian Express To reduce poverty, India needs to concentrate on promoting healthcare and education of the poor It is sometimes argued that a country such as India, aiming to eliminate absolute poverty, should only be concerned about economic growth, and not worry about inequality. Is that right? Yes, growth is (typically) good for the poor but it is no less true that inequality is (typically) bad for the poor. There is little...

-The Times of India NEW DELHI: In yet another twist to the Ranbaxy scandal, the drug regulatory authority of the UK government has issued a statement clarifying that they have found no evidence of any Ranbaxy product in the UK market having been "of unacceptable quality". Last month, WHO had issued a similar statement. It had said that there was no evidence of any of the Ranbaxy products being of unacceptable...